Background: Peritoneal Dialysis (PD) is a renal replacement therapy commonly used in patients with end-stage renal disease (ESRD). Automated PD (APD) is more convenient than traditional continuous ambulatory PD (CAPD) because the manual delivery and drainage of dialysate is not required. Oseltamivir is an oral prodrug widely indicated for the treatment of influenza infections. The […]
2014
ISoP Lecture 2014: What have models ever done for you?
In this talk I will look critically at the role of modelling within drug research. The theme is basically that many people model for modelling sake without thinking what they are doing. Personally I think this gives modelling a bad name and could be dangerous (but probably not). I will go through a number of […]
Estimating the relative potencies of an anticholinergic medicine: A methodological view point
Background Older people continue to be prescribed medicines with anticholinergic properties and are at an increased risk of experiencing adverse events with these medicines.1 Exposure to 1 or more medicines with anticholinergic properties is termed anticholinergic burden.2 Tools to quantify anticholinergic burden have been developed, but the major drawbacks of these tools are the limited […]
Development of a criterion to quantify forgiveness
Background: A variety of patterns of imperfect adherence have been reported including deviations in timing of doses as well as non-consecutive missed doses and drug holidays [1]. Forgiveness is a drug specific property that arises from the relationship of the duration of action and the dose interval of the drug. When the duration of action […]
Population pharmacokinetic model for D-β-Hydroxybutyrate following ketone monoester ingestion
Background: Ketone bodies, the evolutionary response to starvation in humans, are produced in the liver from fatty acids in response to low blood glucose and insulin, and used by the body as fuels. Ketogenic diets have long been used to treat intractable paediatric epilepsy, with therapeutic evidence for ketosis in other neurodegenerative disorders such as […]
Simplification of a pharmacokinetic model for red blood cell methotrexate disposition
Background: Methotrexate (MTX, MTXGlu1) is the gold standard treatment of rheumatoid arthritis. The time course of clinical outcomes is difficult to predict after commencing oral or subcutaneous MTX treatment. A 9-compartment pharmacokinetic (PK) model is available for describing the time course of the concentrations of MTXGlu1 and its polyglutamated metabolites (MTXGlu2-5) in red blood cells […]